About Molbio Diagnostics IPO
Molbio Diagnostics IPO Overview
Molbio Diagnostics IPO is a 100% book-built issue worth up to ₹939.70 crore, comprising a fresh issue of ₹200 crore and an offer for sale (OFS) of 91.66 lakh equity shares worth up to ₹740 crore, with a face value of ₹1 per share. The company filed its DRHP with SEBI on August 22, 2025.
The price band of the issue is set between ₹768 to ₹807 per share and the lot size for an application is 18 shares. The minimum amount of investment required by an individual investor is ₹14,526 (18 shares). The IPO will be open for subscription from August 10 to 12, 2026, on the BSE and the NSE platforms. The book-running lead managers of the issue are Kotak Mahindra Capital, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors, while KFin Technologies Ltd. serves as the registrar to the issue.
Molbio Diagnostics IPO Date & Timeline
The Molbio Diagnostics IPO is officially set to open for subscription on Aug 10, 2026 and will close on Aug 12, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on August 22, 2025 and has now finalised its schedule following SEBI approval. Once the subscription window closes, allotment is expected on Aug 13, 2026. Following this, the firm will initiate refunds and credit shares to successful investors' demat accounts on Aug 14, 2026. Finally, shares of Molbio Diagnostics Ltd. are tentatively scheduled to list on the stock exchanges on Aug 17, 2026.
Molbio Diagnostics IPO Timeline
| IPO Open Date | Mon, Aug 10, 2026 |
| IPO Close Date | Wed, Aug 12, 2026 |
| Tentative Allotment | Thu, Aug 13, 2026 |
| Initiation of Refunds | Fri, Aug 14, 2026 |
| Credit of Shares to Demat | Fri, Aug 14, 2026 |
| Tentative Listing Date | Mon, Aug 17, 2026 |
| Cut-off time for UPI mandate confirmation | - |
Molbio Diagnostics IPO Details
| Detail | Description |
|---|---|
| IPO Date | 10 to 12 Aug, 2026 |
| Listing Date | 17 Aug, 2026 |
| Face Value | ₹ 1 per share |
| Issue Price Band | ₹ 768 to ₹ 807 |
| Lot Size | 18 Shares |
| IPO Type | Fresh capital cum OFS |
| Total Issue Size | 1,16,46,246 shares (agg. up to ₹ 940 Cr) |
| Fresh Issue(Ex Market Maker) | 24,80,246 shares (agg. up to ₹ 200 Cr) |
| Offer for Sale | 91,66,000 shares of ₹1 (agg. up to ₹ 740 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 11,27,59,750 shares |
| Share Holding Post Issue | 11,52,39,996 shares |
Molbio Diagnostics IPO raises ₹281.46 crore from anchor investors. Molbio Diagnostics IPO Anchor bid date is Fri, Aug 7, 2026.
| Bid Date | Fri, Aug 7, 2026 |
| Shares Offered | 34,87,717 |
| Anchor Portion (₹ Cr.) | 281.46 |
| Anchor lock-in period end date for 50% shares (30 Days) | Fri, Sep 11, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Tue, Nov 10, 2026 |
View the official anchor investors letter for complete details.
Download Anchor Letter (PDF)Molbio Diagnostics IPO GMP
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Molbio Diagnostics IPO GMP is currently trading at ₹116, reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹923, which is 14.37% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
IPO Estimated Listing Return
Based on the IPO Price of ₹807 (highest price band), the latest uploaded Grey Market Premium (GMP) of ₹116 and a lot size of 18 shares.
Molbio Diagnostics IPO GMP TREND (DAILY UPDATES)
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 17 Aug 2026 | ₹807 | ₹116 | 17 Aug, 202610:39 AM |
| 16 Aug 2026 | ₹807 | ₹116 | 17 Aug, 202610:39 AM |
| 15 Aug 2026 | ₹807 | ₹116 | 17 Aug, 202610:39 AM |
| 14 Aug 2026 | ₹807 | ₹136 | 14 Aug, 202603:25 PM |
| 13 Aug 2026 | ₹807 | ₹156 | 13 Aug, 202601:08 PM |
| 12 Aug 2026 | ₹807 | ₹143 | 12 Aug, 202605:09 PM |
| 11 Aug 2026 | ₹807 | ₹122 | 11 Aug, 202601:09 PM |
| 10 Aug 2026 | ₹807 | ₹120 | 10 Aug, 202601:11 PM |
| 9 Aug 2026 | ₹807 | ₹132 | 10 Aug, 202610:08 AM |
| 8 Aug 2026 | ₹807 | ₹130 | 8 Aug, 202610:10 AM |
| 7 Aug 2026 | ₹807 | ₹180 | 7 Aug, 202605:32 PM |
| 6 Aug 2026 | ₹807 | ₹210 | 6 Aug, 202603:54 PM |
| 5 Aug 2026 | ₹807 | ₹170 | 6 Aug, 202610:02 AM |
| 04 Aug, 2026 | ₹807 | ₹0 | 04 Aug, 202604:33 PM |
Company Background
Molbio Diagnostics Ltd. was incorporated as a private limited company in Panaji, Goa, on October 20, 2000. The company developed from a private entity into a public limited company to proceed with its public listing procedures, receiving its fresh certificate of incorporation as Molbio Diagnostics Ltd. on January 16, 2025.
The headquarters of the company is in Verna, Goa and for over 20 years, the growth of Molbio has been remarkable, from its roots in specialised diagnostics to a globally recognised name in molecular testing. It focuses on making high-end medical technology accessible and affordable at the point of care.
Operations & Product Range
Molbio Diagnostics Ltd. specialises in the development, manufacturing and sale of molecular diagnostic platforms and kits. The core service involves providing rapid, battery-operated and "plug-and-play" diagnostic solutions that can operate outside traditional laboratory settings.
Its flagship products include the Truenat real-time PCR platform, which is used for detecting various infectious diseases. Molbio Diagnostics Ltd.’s product range covers a wide spectrum of health challenges, including TB, COVID-19, Hepatitis and other viral and bacterial infections, targeting government health departments, private laboratories and international health organisations.
Facilities & Capacity
Molbio Diagnostics Ltd. maintains dedicated infrastructure for both large-scale production of diagnostic kits and the precision assembly of its molecular diagnostic devices. Molbio Diagnostics Ltd. operates primarily out of its facilities in Goa. These include:
- • Goa Unit I: Located at Verna Industrial Estate, this is a key manufacturing facility for the company.
- • Goa Unit II: Also situated in the Verna Industrial Estate, providing additional manufacturing and operational support.
Brands & Market Presence
The most well-known brand under Molbio Diagnostics Ltd. is Truenat (chip-based molecular diagnostic tests), which has gained international recognition for its role in tuberculosis (TB) screening and diagnosis. The company has a strong domestic presence across India, serving both public and private health sectors.
On the export front, Molbio Diagnostics Ltd. has significant exposure, with revenue from customers outside India reaching ₹197.14 crore for the year ended March 31, 2025. Its technology is widely utilised in global health programmes supported by international bodies.
Revenue Streams & Business Model
Molbio Diagnostics Ltd. operates a razor-and-blade business model centred on its proprietary Truenat point-of-care molecular diagnostics ecosystem. The company generates primary revenue from recurring high-margin sales of microchip PCR test reagents and single-use kits. Secondary revenue streams include the initial placement of portable Truenat analysers, ongoing system maintenance and multi-year diagnostic service agreements across public health programmes, private laboratories and international healthcare institutions.
Financial Performance
Molbio Diagnostics Ltd. reported total income of ₹1,455.17 crore in FY26, growing by 20%+ year-on-year from ₹1,027.9 crore in FY25. The company's net profit surged to ₹164.14 crore in FY26, up from ₹138.6 crore in FY25. Driven by strong demand for its flagship Truenat testing platform, the firm achieved an EBITDA margin of 22.56% and expanded total assets to ₹2,148.42 crore.
Management & Shareholding
The promoters of Molbio Diagnostics Ltd. are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP. Before the IPO, the promoters held a 46.65% stake in the company, but after the IPO, the promoters’ shareholding will be diluted as the offering includes 91.66 lakh equity shares to be sold by the existing shareholders.
Board & Key Management
The leadership of Molbio Diagnostics Ltd. is led by a team of experts with many years of experience. Sangeetha Sriram serves as the Chairman and gives strategic direction to the firm. The daily operations are managed by Indraneil Borkakoty, the Managing Director, along with Whole-Time Directors, Sriram Natarajan, Dr. Chandrasekhar Nair and Sangeetha Sriram. To ensure good governance, the board includes Independent Directors, Nupur Garg, Dr. Balram Bhargava and Dr. Arun Kumar Jha for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.
Molbio Diagnostics IPO Financial Information
Latest Revenue
₹ 1,445.69 Cr
Profit After Tax
₹ 164.14 Cr
Net Worth
₹ 1,144.68 Cr
Total Borrowing
₹ 412.64 Cr
| Period Ended | Assets | Revenue | Profit (PAT) | Net Worth | Reserves | Borrowing |
|---|---|---|---|---|---|---|
| 31 Mar 2026 | 2,148.42 | 1,445.69 | 164.14 | 1,144.68 | 1,148.84 | 412.64 |
| 31 Mar 2025 | 1,034.21 | 1,020.42 | 138.58 | 952.95 | 966.13 | 123.16 |
| 31 Mar 2024 | 1,221.06 | 836.56 | 83.54 | 807.94 | 821.12 | 174.58 |
| 31 Mar 2023 | 1,461.56 | 332.46 | -3.45 | 706.04 | 719.22 | 108.44 |
| Amount in ₹ Crore | ||||||
Molbio Diagnostics Key Performance Indicator
| KPI | Values(31 Mar 2026) |
|---|---|
| ROE | 15.59 % |
| ROCE | 17.55 % |
| Debt/Equity | - |
| RoNW | 14.55 % |
| PAT Margin | 11.28 % |
| EBITDA Margin | 22.56 % |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 14.56 | 14.24 |
| P/E (x) | 55.43 | 56.67 |
IPO Objectives
The company intended to utilise the Molbio Diagnostics IPO proceeds for the strategic purposes:
- • Repayment or prepayment of outstanding borrowings (in part or in full).
- • Funding capital expenditure for expansion and modernisation.
- • Investment in research and development (R&D) to broaden the product portfolio.
- • General corporate purposes.
IPO Review
Molbio Diagnostics Ltd. is a leading Indian molecular diagnostics firm focused on developing and manufacturing point-of-care diagnostic solutions. Its flagship Truenat platform enables rapid detection of infectious diseases such as tuberculosis, COVID-19, malaria and hepatitis. The company has built a strong presence across India and several international markets, supported by continuous innovation, an extensive installed base and collaborations with healthcare institutions, giving it a credible position in the molecular diagnostics industry.
Financially, the company has shown growing and profitable statements. For FY25, the company reported revenue from operations of ₹1,020.4 crore, compared with ₹836.6 crore in FY24, reflecting a year-on-year growth of around 22%. PAT increased to ₹138.6 crore from ₹83.5 crore in the previous year, registering an impressive growth of nearly 66%. The improvement was driven by higher sales, improved operating efficiency and a stronger product mix.
However, investors should note that the company derives a significant portion of its revenue from a limited number of diagnostic platforms and products. The business also depends on regulatory approvals, government healthcare spending, timely procurement orders and continuous technological innovation. Any disruption in these areas or increased competition could affect future growth and profitability.
Overall, this IPO demonstrates strong financial growth, technological leadership and attractive industry prospects. However, investors should carefully monitor regulatory, product concentration and execution risks before making a long-term investment decision.
Conclusion
Molbio Diagnostics IPO brings a chance for investors to invest in a technologically driven healthcare company that has built a business model centred on high-volume diagnostic kit sales and a strong hardware platform and has gained an international market reach, with a focus on point-of-care solutions to address a critical gap in the healthcare infrastructure of developing economies. With this listing, the company aims to leverage its execution focus and R&D capabilities to tap into further opportunities in the diagnostic industry.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The INDIA IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
The Truenat platform is a patented, point-of-care molecular diagnostic technology that allows for laboratory-grade testing in field conditions.
Established global footprint and validation from global health organisations.
In-house facilities in Goa allow for end-to-end control over the production of both devices and consumables.
Demonstrated ability to ramp up production and distribution, as seen during the rapid deployment of testing kits in recent years.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 1 | 18 | 14,526 |
| Individual investors (Retail) (Max) | 13 | 234 | 1,88,838 |
| S-HNI (Min) | 14 | 252 | 2,03,364 |
| S-HNI (Max) | 68 | 1,224 | 9,87,768 |
| B-HNI (Min) | 69 | 1,242 | 10,02,294 |